Maria Padilla, MD
Enriched profileProfessor of Medicine, Pulmonary, Critical Care and Sleep Medicine; Director, Advanced Lung Disease/Interstitial Lung Disease Program · Icahn School of Medicine at Mount Sinai
Maria Padilla is Professor of Medicine, Pulmonary, Critical Care and Sleep Medicine; Director, Advanced Lung Disease/Interstitial Lung Disease Program at Icahn School of Medicine at Mount Sinai. OpenAlex indexes 108 publications with 4,056 citations (h-index 32); ClinicalTrials.gov lists 6 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 31 Aug 2026
Maria L. Padilla, MD, is Professor of Medicine, Pulmonary, Critical Care and Sleep Medicine at Icahn School of Medicine at Mount Sinai. The public record shows 108 publications with 4,056 citations (h-index 32), centered on Idiopathic Pulmonary Fibrosis. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 6 companies, 1 NIH-funded awards (1985–1986).
- Top research focus: Idiopathic Pulmonary Fibrosis
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 6 companies
Generated from the cited public record · current as of 31 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 31 Aug 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Sponsor: Rein Therapeutics
- An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Sponsor: Avalyn Pharma Inc.
- Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Sponsor: Cumberland Pharmaceuticals
Industry payments
Updated 31 Aug 2026
6 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202511 payments
- United Therapeutics CorporationProgram year202510 payments
- Insmed, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
35.4%Corticosteroid24%Trelegy Ellipta55%Breo Ellipta31%Qvar Redihaler7%Fluticasone Propionate7%Part D<11 patientsbeta2-Adrenergic Agonist6%Albuterol Sulfate Hfa100%Part D≥17 patientsCancer & immunology
30%Kinase inhibitor17.6%Ofev100%Part D≥26 patientsPyridone12.4%Pirfenidone100%Part D≥20 patientsMetabolism & gastrointestinal
21.5%Corticosteroid11.1%Prednisone100%Part D≥40 patientsProton pump inhibitor8.5%Omeprazole87%Esomeprazole Magnesium13%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 31 Aug 2026
1 NIH research award on record, funded 1985–1986 per NIH RePORTER. The latest:
- Establishment and visualization of nuclear architecture at the onset of mammalian development
Helmholtz Zentrum Muenchen - Gmbh
FY2023$393,866U01DK127391 - Establishment and visualization of nuclear architecture at the onset of mammalian development
Helmholtz Zentrum Muenchen - Gmbh
FY2022$393,866U01DK127391 - Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis
National Jewish Health
FY2021$1,511,058UH3TR002445
Publications
None on file yet. We only list publications we can confidently match to this person. Why? →
Online presence
Updated 31 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/maria-padilla-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
scholars.mssm.edu/en/persons/maria-padilla
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗
Mentions by others
where others cite or feature them- Other
ajmc.com/view/key-ild-topics-at-mount-sinai-s-advances-in-pulmonary-medicine-2024
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ajmc.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 31 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Mount Sinai School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →rheumatologyacademy.org ↗
Editorial & leadership roles
journal and society appointments- Medical Director
Lung Transplantation Program, The Mount Sinai Medical Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - Director
Interstitial Lung Disease Program, Mount Sinai - National Jewish Health Respiratory Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - Board certified: Internal Medicine
Pulmonary Medicine, Critical Care Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →rheumatologyacademy.org ↗
- Jacobi Medallion
Mount Sinai Hospital
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →rheumatologyacademy.org ↗ - Saul Horowitz Jr. Memorial Award
Mount Sinai
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →rheumatologyacademy.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗
- Member
International Society of Heart and Lung Transplantation (ISHLT)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Media & interviews
press, podcasts and appearances- Interview: "Key ILD Topics at Mount Sinai's Advances in Pulmonary Medicine 2024"
previewed the Mount Sinai Respiratory Institute's Advances in Pulmonary Medicine 2024 conference …
2024provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ajmc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Jonathan Halperin, MD
Icahn School of Medicine at Mount Sinai
Fred Lublin, MD
Icahn School of Medicine at Mount Sinai
Sundar Jagannath, MD
Icahn School of Medicine at Mount Sinai